MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 519-528

  Wu, Jianmin ^a   Wu, Gang ^b   Lv, Lu ^a   Ren, Yong Feng ^a   Zhang, Xue Jiao ^a   Xue, Yong Feng ^a   Li, Guiling ^a   Lu, Xincheng ^a   Sun, ZhongSheng ^a   Tang, Kai Fu ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MICRORNA; MICRORNA 34A; PROTEIN P53; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER TISSUE; CELL MIGRATION; COLON CANCER; DNA BINDING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 84863230238     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr304     Document Type: Article

References (47)

1. Jemal,A. et al. (2010) Cancer statistics, 2010. CACancer J. Clin., 60, 277-300.
2. Steeg,P.S. (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer, 3, 55-63.
3. Fidler,I.J. (2002) Critical determinants of metastasis. Semin. Cancer Biol., 12, 89-96.
4. Babashah,S. et al. (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur. J. Cancer, 47, 1127-1137.
5. Calin,G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
6. Ventura,A. et al. (2009) MicroRNAs and cancer: short RNAs go a long way. Cell, 136, 586-591.
7. Iorio,M.V. et al. (2009) MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol., 27, 5848-5856.
8. Place,R.F. et al. (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl Acad. Sci. USA, 105, 1608-1613.
9. Garzon,R. et al. (2009) MicroRNAs in cancer. Annu. Rev. Med., 60, 167-179.
10. Lim,L.P. et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769-773.
11. Liu,M. et al. (2010) The role of microRNAs in colorectal cancer. J. Genet. Genomics, 37, 347-358.
12. Gaur,A. et al. (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res., 67, 2456-2468.
13. Chang,T.C. et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.
14. Li,N. et al. (2009) miR-34a inhibits migration and invasion by downregulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett., 275, 44-53.
15. Tazawa,H. et al. (2007) Tumor-suppressive miR-34a induces senescencelike growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl Acad. Sci. USA, 104, 15472-15427.
16. Hermeking,H. (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ., 17, 193-199.
17. Raver-Shapira,N. et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell, 26, 731-743.
18. Tarasov,V. et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6, 1586-1593.
19. He,L. et al. (2007) A microRNA component of the p53 tumor suppressor network. Nature, 447, 1130-1134.
20. Li,Y. et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res., 69, 7569-7576.
21. Wei,J.S. et al. (2008) The MYCN oncogene is a direct target of miR-34a. Oncogene, 27, 5204-5213.
22. Yamakuchi,M. et al. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA, 105, 13421-13426.
23. Yan,D. et al. (2009) MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci., 50, 1559-1565.
24. Pang,R.T. et al. (2010) MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis, 31, 1037-1044.
25. Eferl,R. et al. (2003) AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer, 3, 859-868.
26. Milde-Langosch,K. (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer, 41, 2449-2461.
27. Adiseshaiah,P. et al. (2007) FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res., 67, 6204-6211.
28. Adiseshaiah,P. et al. (2008) A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J. Cell. Physiol., 216, 405-412.
29. Belguise,K. et al. (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene, 24, 1434-1444.
30. Luo,Y.P. et al. (2010) The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene, 29, 662-673.
31. Andreolas,C. et al. (2008) Fra-1 regulates vimentin during Ha-RASinduced epithelial mesenchymal transition in human colon carcinoma cells. Int. J. Cancer, 122, 1745-1756.
32. Pollock,C.B. et al. (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res., 65, 1244-1250.
33. Vial,E. et al. (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell, 4, 67-79.
34. Choong,M.L. et al. (2009) Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle, 8, 2810-2818.
35. Mischo,H.E. et al. (2005) Actinomycin D induces histone gamma-H2AX foci and complex formation of gamma-H2AX with Ku70 and nuclear DNA helicase II. J. Biol. Chem., 280, 9586-9594.
36. Westermarck,J. et al. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 13, 781-792.
37. Hendrix,M.J. et al. (1997) Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol., 150, 483-495.
38. Clark,I.M. et al. (2008) The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol., 40, 1362-1378.
39. Ramos-Nino,M.E. et al. (2003) Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res., 63, 3539-3545.
40. Vial,E. et al. (2003) Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci., 116, 4957-4963.
41. Casalino,L. et al. (2003) Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol. Cell Biol., 23, 4401-4415.
42. Vogelstein,B. et al. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799.
43. Vogelstein,B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
44. Hollstein,M. et al. (1999) New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res., 431, 199-209.
45. Sporn, M.B. (1996) The war on cancer. Lancet, 347, 1377-1381.
46. Holgren,C. et al. (2010) Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene, 29, 5241-5253.
47. Ma,P.C. et al. (2007) Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br. J. Cancer, 97, 368-377.